DIABETIC DRUG ASSESSED FOR USE IN PARKINSON'S DISEASE

VIARTIS

�

�PARKINSON'S DISEASE NEWS

Amazon.com Widgets

�

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

��

�

4th August 2017 - New research

DIABETIC DRUG ASSESSED FOR USE IN PARKINSON'S DISEASE

�CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

Exenatide is a type 2 diabetes treatment that differs in its pharmacological action and structure from insulin. Exenatide is an injected glucagon-like peptide-1 agonist. The possible means of how it might affect Parkinson's Disease is not known. It has no direct effect on dopamine.

The effects of exenatide were assessed in people with moderate Parkinson's Disease. The primary outcome was the adjusted difference in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale (part 3). After over a year, off-medication scores on part 3 of the MDS-UPDRS had improved by only 1�0 point in people taking exentaide and worsened in people taking a placebo.� Although it has been claimed that exenatide can slow down Parkinson's Disease the efficacy is too mild to justify such claims. Injection site reactions and gastrointestinal symptoms were common adverse events in both groups.

In four previous studies the efficacy was also found to be mild. Unusually, the effects of exenatide on Parkinson's Disease had continued to some extent beyond its use. In those studies exenatide was well tolerated but weight loss was common. Other adverse effects of the use of exenatide were nausea, injection-site induration, dyslipidemia, vomiting, diarrhoea, headache and hypoglycaemia.

Reference : The Lancet [2017] S0140-6736(17)31585-4390 (D.Athauda, K.Maclagan, S.S.Skene, M.Bajwa-Joseph, D.Letchford, K.Chowdhury, S.Hibbert, N.Budnik, L.Zampedri, J.Dickson, Y.Li, I.Aviles-Olmos, T.T.Warner, P.Limousin, A.J.Lees, N.H.Greig, S.Tebbs, T.Foltynie) Complete abstract� For more news go to Parkinson's Disease News

�

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,� please merely e-mail [email protected] with the message "subscribe".� No form of identity is required.� E-mail addresses are not used for any other purpose.

GO TO PARKINSON'S DISEASE HOME PAGE

�

THE COMPREHENSIVE GUIDE TO PARKINSON'S DISEASE

The Comprehensive Guide to Parkinson's Disease, which is fully referenced, and over 800 pages long, is the most comprehensive book concerning Parkinson's Disease. It includes the history of Parkinson 's Disease, famous people with Parkinson's Disease, the complete biochemisty of Parkinson's Disease, its cytology and cytological effects, anatomy and anatomical effects, physiology and physiological effects, symptoms of every system in the body, the diagnosis methods (observational, technological, chemical), biochemical causes, all the toxic causes, all the genetic causes, all the pharmacological causes, all the medical disorders that cause Parkinson's Disease symptoms, its treatments (biochemical, pharmacological, surgical, natural, exercise methods, technological methods), including all those treatments that exist and all those treatments presently being developed, Parkinson's Disease organisations, Parkinson's Disease web sites, and books on Parkinson's Disease nursing. CLICK HERE FOR MORE DETAILS

�

�

�2006-2017� Viartis

�

2017-08-04 12:38:29

�

[email protected]

More great reads